The Danish Health Authority has appointed Novo Nordisk's new drug Ozempic asfirst choice of GLP-1 analogues for treating type 2diabetes. However, it does not apply to patients with cardiovascular problems or the eye disease diabetic retinopathy.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.